. 2021 Aug;9(15):1226. doi: 10.21037/atm-21-1803
2021 Annals of Translational Medicine. All rights reserved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.
Figure 4.
Scatterplot of the incremental cost–effectiveness ratio of camrelizumab vs. chemotherapy.